Sub-components in Nicotine cessation products?
|
|
- Pauline Reed
- 5 years ago
- Views:
Transcription
1 Sub-components in Nicotine cessation products? Mr Arun Sarda, Director of Quality and Regulatory Affairs Member of the HEITKAMP & THUMANN GROUP
2 Regulatory approval of sub-components in nicotine cessation products? Introduction to H&T Presspart Group - Pharmaceutical Pedigree Identifying the regulatory pathway for successful approval of Nicotine cessation products, using pharma/medicinal approved subcomponents? Regulatory strategy for sub-components used in the manufacture of Nicotine cessation products, using existing technologies, applying 40 years of know-how. 2
3 H&T Presspart s pharmaceutical pedigree 1970: Presspart Manufacturing is founded in Blackburn UK, manufacturing of industrial metal components and MDI (metered dose inhaler) cans. writer/title date 3
4 H&T Presspart s pharmaceutical pedigree 2009: Production of components and sub-assemblies of nasal inhalation devices begins at Presspart Tarragona, Spain writer/title date 4
5 H&T Presspart s pharmaceutical pedigree 2010: Novel plasma surface treatment process developed, offering unique surface treatment of the canister, minimising drug adhesion. 2011: Development of MDI actuators with integrated Dose Indicator and Dose Counter mechanisms begins at Presspart Tarragona. (Meet EOL indication regulatory requirements) 2012: Creation of the Presspart R&D facility, Inhalation Product Technology Centre (IPTC), Blackburn, UK. 2016: Presspart launches the first market-ready smart connected MDI (emdi). writer/title date 5
6 H&T Presspart today As a global market leader, H&T Presspart provides innovative drug delivery device solutions for clients in the pharmaceutical sector. Blackburn, UK Marsberg, Germany North Carolina, USA Shanghai, China Tarragona, Spain Mumbai, India Montevideo, Uruguay Manufacturing Sales Offices 6
7 H&T Presspart today 36 countries We maintain world-class manufacturing facilities and supply components and devices to 36 countries. 900 million In 2014, we manufactured over 900 million MDI cans, actuators assembled devices and plastic components. 400 employees We employ over 400 employees across our three European sites. [UK, Germany, Spain] 40 years We have over 40 years experience in manufacturing high volume components for the pharmaceutical market. 75% market share We manufacture components for over 75% of the world s MDIs. 8 million Over EUR 8 million invested in product development, manufacturing capabilities and capacities in
8 H&T Presspart today Our clients are world leaders within the Industry 8
9 H&T Presspart today Blackburn, UK site Aluminium MDI cans: Plain (uncoated) Plasma treated Anodised Stainless steel MDI cans MDI valve components Inhalation Product Technology Centre (R&D) Industrial & Speciality products Operate a ISO8 clean room writer/title date 9
10 H&T Presspart today- Marsberg, Germany site Aluminium MDI cans: o Internally spray coated Components for other OINDP (Orally Inhaled Nasal Drug products) devices, e.g. Respimat Clean Room environment & GMP writer/title date 10
11 H&T Presspart today- Tarragona, Spain site MDI actuator components and assemblies Speciality actuators for nasal, mouth and throat sprays Components & sub-assemblies for other drug delivery systems and medical devices ISO7 CR medical devices ISO8 CR plastic injection moulding writer/title date 11
12 Quality Management Systems ISO 9001: Quality Management Systems Presspart Blackburn originally achieved certification to BS 5750 (1980 s) Presspart Marsberg and Tarragona site both achieved ISO 9001 certification in 1997 ISO 15378: Primary packaging materials for medicinal products Presspart Tarragona became the first Spanish company to achieve certification in May 2008 ISO 13485: QMS for manufacture of Medical devices Presspart Tarragona achieved certification in June 2010 writer/title date 12
13 Material and product registrations H&T Presspart Drug Master Files filed with US FDA 07407: Aluminium Alloy MDI Cans 15078: MDI Cans Internally Coated with Fluoropolymer 16266: Stainless Steel MDI Cans 17299: Respimat Device Container 18569: MDI Cans Anodised and Internally Coated 21589: MDI Cans Internally Coated with FEP Fluoropolymer 23253: Veramyst Intranasal Device 30434: MDI Actuators 30520: Plasma Surface Treatment writer/title date 13
14 H&T Presspart and nicotine products US FDA Health Document Submission Requirements for Tobacco Products (Draft Guidance for Industry) Product Master Files from February 2017 (similar to Drug Master Files or pharma products). Why has the TPD been revised? 1) New scientific evidence emerged on tobacco flavourings and on the effect of health warning. 2) New products, such as e-cigarettes and strong flavoured tobacco products have emerged on markets. 3) Provide consistent regulatory framework for all Member States in EU. writer/title date 14
15 With the regulatory requirements and framework of the TPD (2014/14/EU) H&T Presspart are excited to be a key business partner in launching new innovative, safe, good quality products for the Nicotine Delivery industry. Do we think the components of Nicotine products in the future will contain a H&T Presspart MDI canister/sub-component(s) of some type? We think so. writer/title date 15
16 Thank You Member of the HEITKAMP & THUMANN GROUP Arun Sarda Global Director, Quality & Regulatory Affairs
Partner with the Global Leader in Drug Delivery Systems
3M DRUG DELIVERY SYSTEMS Partner with the Global Leader in Drug Delivery Systems Loughborough, United Kingdom Manufacturing Facility Experts at Commercializing Innovation 3M: Transforming New Ideas into
More informationCaption: The equipment required for testing Fluticasone Propionate (FP) Inhalation Powder in line with a new product-specific monograph (USP36-NF31).
Product-specific FDA guidance, and product-specific pharmacopeial monographs, point to the use of test equipment, some of which isn t included in the general USP/Ph. Eur. chapters for orally inhaled products
More informationDevice Change Management for Inhaled Products. Loy Britto, Ph.D. GlaxoSmithKline ISAM Congress Munich 2015
Device Change Management for Inhaled Products Loy Britto, Ph.D. GlaxoSmithKline ISAM Congress Munich 2015 Topics to be covered Update on ISO/TC 084/WG 15: Guidelines for development of drug products- Quality
More informationPartner with the Global Leader in Drug Delivery Systems.
3M DRUG DELIVERY SYSTEMS Partner with the Global Leader in Drug Delivery Systems. Hurlingham, Argentina Manufacturing Facility Experts at Commercializing Innovation Drug Delivery Systems: It s in the detail
More informationPartner with the Global Leader in Drug Delivery Systems.
3M DRUG DELIVERY SYSTEMS Partner with the Global Leader in Drug Delivery Systems. Hurlingham, Argentina Manufacturing Facility Experts at Commercializing Innovation 3M is a global innovation company that
More informationInternational Pharmaceutical Aerosol Consortium on Regulation and Science
International Pharmaceutical Aerosol Consortium on Regulation and Science 1500 K Street NW Washington DC 20005 Telephone +1 202 230 5607 Fax +1 202 842 8465 Email info@ipacrs.org Web www.ipacrs.org Submitted
More informationBoehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider
Boehringer Ingelheim Biopharmaceuticals in China Your Reliable Contract Manufacturing Solution Provider Dr. Bin Wang, Dr. Axel Schleyer Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. Contact:
More informationQualifying Container Closure Systems for OINDP: Current & Future Regulatory Expectations. Julie D. Suman, Ph.D. November 14, 2014
Qualifying Container Closure Systems for OINDP: Current & Future Regulatory Expectations Julie D. Suman, Ph.D. November 14, 2014 Objectives Container-Closure System Attributes Extractables Regulatory Expectations
More informationH&T Presspart and Cohero Health Launch First Market-Ready, Fully-Connected Metered Dose Inhaler to Optimize care of Asthma and COPD
H&T Presspart and Cohero Health Launch First Market-Ready, Fully-Connected Metered Dose Inhaler to Optimize care of Asthma and COPD emdi enables improved adherence, engagement in self-care and real-time
More informationADVANCIA : A TRUE PLATFORM & INNOVATIVE SYSTEM OFFERING EFFICIENT NASAL DOSE DELIVERY
ADVANCIA : A TRUE PLATFORM & INNOVATIVE SYSTEM OFFERING EFFICIENT NASAL DOSE DELIVERY Millions of people suffering from allergic rhinitis use nasal sprays manufactured by Nemera every day. In this article,
More informationMeasuring Emissions as Part of a Regulatory Regime. Prof. Riccardo Polosa Professor of Internal Medicine and Convenor CEN TC437/WG4
Measuring Emissions as Part of a Regulatory Regime Prof. Riccardo Polosa Professor of Internal Medicine and Convenor CEN TC437/WG4 . (b) a list of all ingredients contained in, and emissions resulting
More informationA proposed bridging approach for the assessment of novel tobacco products
A proposed bridging approach for the assessment of novel tobacco products Dr. Ian M. Fearon British American Tobacco (Investments) Limited R&D Centre Southampton, U.K. Agenda Insight into BAT R&D Evolution
More informationUNITED STATES REGULATION OF TOBACCO PRODUCTS. Presented by Mitch Zeller Center Director FDA Center for Tobacco Products
UNITED STATES REGULATION OF TOBACCO PRODUCTS Presented by Mitch Zeller Center Director FDA Center for Tobacco Products May 24, 2016 OVERVIEW OF TODAY S PRESENTATION Highlights of the Deeming Final Rule
More informationGLOBAL TOBACCO REGULATION OVERVIEW IVAN GENOV RESEARCH ANALYST 31 MAY 2018
IVAN GENOV RESEARCH ANALYST 31 MAY 2018 Three tiers of regulations affecting the industry 2 Core Advertising and sponsorship bans Descriptor bans Tax-driven excise increases Standard Public smoking bans
More information040716_ANDI_VENTIS WEBSITE(new) Printout 1. HOME PAGE. Welcome to our world of Dry Powder Inhalers!
1. HOME PAGE Welcome to our world of Dry Powder Inhalers! Andi-Ventis Ltd, established in 2001 is a joint venture between Medochemie Ltd, Cyprus and Miat SpA Italy, founded to carry out the pharmaceutical
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationMedical Developments International
Medical Developments International Vision Medical Developments International (MDI) is a leading Emergency Medicine Company. Our aim is to 1. Dominate the analgesic trauma and minor surgical procedures
More informationISO 13485:2016 MEDICAL DEVICES QMS TRANSITION GUIDE
ISO 13485:2016 MEDICAL DEVICES QMS TRANSITION GUIDE ISO 13485, OVERVIEW ISO 13485 sets regulatory requirements or, when specified, customer requirements for a management system for medical devices or services.
More informationGraft Delivery Devices
Graft Delivery Devices About Graft Delivery Devices Nordson MEDICAL Nordson MEDICAL is your partner in the global life sciences market providing innovative components, devices and custom OEM solutions
More informationDissolvable Tobacco Products
Dissolvable Tobacco Products James E. Dillard Senior Vice President, Regulatory Affairs Altria Client Services 1 l Altria Client Services (on behalf of PM USA and USSTC) I Presentation to the Tobacco Products
More informationCOMMENTS. Submitted by The International Pharmaceutical Aerosol Consortium
COMMENTS on a draft Guidance for Industry Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products Chemistry, Manufacturing, and Controls Documentation (Docket No. 99D-1454) Submitted by
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationTechnology and Quality of Inhalation Drug Products
Technology and Quality of Inhalation Drug Products Good Development Practices, Specifications, and Analytical Methods for Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Respiratory Drugs 5 6 November
More informationREFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Protopic in the nine major pharmaceutical markets
More informationA combination of licensed medication and professional support is four times more likely to achieve a stop in smoking behaviour.
PHA Position Statement E-cigarettes 30 May 2014 The Public Health Agency (PHA) considers E-cigarettes with caution at this time. E-cigarettes are not licensed nicotine replacement products. They are not
More informationUnderstanding Regulatory Global Requirements for Nasal Drug Products. Julie D. Suman, Ph.D. April 8, 2016
Understanding Regulatory Global Requirements for Nasal Drug Products Julie D. Suman, Ph.D. April 8, 2016 AGENDA NDA vs ANDA Regulatory Approaches for Bioequivalence (BE) FDA Drug Specific Guidances FDA,
More informationREFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Elidel in the major pharmaceutical markets: the
More informationConsultation on Electronic Cigarettes. Analysis of submissions
Consultation on Electronic Cigarettes Analysis of submissions Released 2017 health.govt.nz Citation: Ministry of Health. 2017. Consultation on Electronic Cigarettes: Analysis of submissions. Wellington:
More informationThe English experience in a European regulatory context. E-cigarette summit Washington DC 1 st May 2018 Deborah Arnott Chief Executive ASH (UK)
The English experience in a European regulatory context E-cigarette summit Washington DC 1 st May 2018 Deborah Arnott Chief Executive ASH (UK) Declaration of Interest ASH (UK) is a public health charity
More informationTesting Inhaled Generics
Generic Bioequivalence Testing Inhaled Generics By Mark Copley at Copley Scientific New product-specific FDA guidance and USP monographs support the development of popular inhaled products. This article
More informationUpdate from FDA Office of Regulatory Affairs
Update from FDA Office of Regulatory Affairs Ellen F. Morrison Assistant Commissioner for Medical Products and Tobacco Operations Office of Regulatory Affairs U.S. Food and Drug Administration 1 The Impact
More informationRegulatory Support for Tobacco Products. Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help.
Regulatory Support for Tobacco Products Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help. PREMARKET TOBACCO (PMTA) HUMAN FACTORS STUDIES SUBSTANTIAL EQUIVALENCE
More informationREFERENCE CODE GDHC296DFR PUBLICATION DATE NOVEMBER 2013 DUPILUMAB (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC296DFR PUBLICATION DATE NOVEMBER 2013 DUPILUMAB (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Dupilumab in the nine major pharmaceutical markets
More informationLocation of HENGRUI. The Headquarters: No.7 Kunlunshan Road, Economic & Technological Development Zone Lianyungang, Jiangsu, China
1 Location of HENGRUI The Headquarters: No.7 Kunlunshan Road, Economic & Technological Development Zone Lianyungang, Jiangsu, China 2 Domestic Achievements No. 1 in Market Cap No. 1 in Innovation No. 1
More informationE-Cigarette Product Regulation and Standardisation
E-Cigarette Product Regulation and Standardisation Derek Mariner British American Tobacco, Research & Development, Southampton UK E-cigarette Workshop, Paper STW03 CORESTA Smoke Science and Product Technology
More informationWhat's Important to Consider When Developing a Complex Generic Drug? September 5, 2018
What's Important to Consider When Developing a Complex Generic Drug? September 5, 2018 Session Description FDA has provided drug manufacturers tools to assist the development of complex generic drugs to
More informationPolicy Options for the Regulation of Electronic Cigarettes
Policy Options for the Regulation of Electronic Cigarettes Consultation submission Your details This submission was completed by: (name) Philip Hope / Assoc Prof Chris Atkinson Address: (street/box number)
More information2. Develop teams of four students (there are seven unique roles in ABIG Company).
ROLE-PLAY EXERCISE QRS AsthmaCare Products, Inc. PROCESS 1. Make copies of the role-play exercise pages (one copy of background page for each student in the class; one set of four roles for every four
More informationREGULATORY OPTIONS FOR MOVING TO THE ELIMINATION OF SMOKING. Ron Borland PhD
REGULATORY OPTIONS FOR MOVING TO THE ELIMINATION OF SMOKING Ron Borland PhD Tobacco Smoking Extremely harmful to health Kills over half of long-term users Reduces quality life years in most Slows recovery
More informationQuality of Nasal and Inhalation Drug Products
Quality of Nasal and Inhalation Drug Products Good Development Practices, Specifications, and Analytical Methods for Inhalation Drug Products (Metered Dose Inhaler (MDI), Dry Powder Inhaler (DPI)) and
More informationHARM REDUCTION The opportunity
HARM REDUCTION The opportunity Sustainability Focus Report 2014 CLICK TO READ 1 8 STEP INSIDE: VIDEO TOUR OF OUR R&D LABS HARM REDUCTION A NEW WAY FORWARD? WHAT IS HARM REDUCTION? 2 7 TRANSPARENCY AND
More informationQuality Management System Certification. Understanding Quality Management System (QMS) certification
Quality Management System Certification Understanding Quality Management System (QMS) certification The medical device manufacturing sector is one of the most regulated sectors in which significant quality
More informationMerrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004
Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations
More informationWHO Framework Convention on Tobacco Control
WHO Framework Convention on Tobacco Control When WHO was established in 1948, its Member States incorporated the power to negotiate treaties into its Constitution. This power remained dormant until 1996,
More informationACS Submission: Consultation on the advertising of electronic cigarettes
ACS Submission: Consultation on the advertising of electronic cigarettes ACS (the Association of Convenience Stores) welcomes the opportunity to respond to Committee of Advertising Practices consultation
More informationTHE DEVELOPMENT PATH TO BIOEQUIVALENCE FOR A NASAL SPRAY
THE DEVELOPMENT PATH TO BIOEQUIVALENCE FOR A NASAL SPRAY In this article Pascale Farjas, Global Category Manager, ENT Products, Alain Regard, Technology Product Manager, and Céline Petitcolas, Customer
More informationPolicy Options for the Regulation of Electronic Cigarettes
Policy Options for the Regulation of Electronic Cigarettes Consultation submission Your details This submission was completed by: Address: (name) Mark Forsyth (street/box number) 3 Queens Wharf (town/city)
More informationA NEW, ADVANCED HIGH- THROUGHPUT SYSTEM FOR AUTOMATED INHALER TESTING
A NEW, ADVANCED HIGH- THROUGHPUT SYSTEM FOR AUTOMATED INHALER TESTING Two years ago, Novi Systems Ltd set out to shake up the inhaler automation market. On December 8th, 2015, at the Drug Delivery to the
More informationCollecting and Handling Health Data in a GDPR World
Collecting and Handling Health Data in a GDPR World Alexander Whalen, Senior Policy Manager, DIGITALEUROPE @DIGITALEUROPE WHO IS Represents the digital technology sector in Europe A wide range of Multinational
More informationModified Risk Tobacco Product Applications A Succinct ENDS Industry Perspective
Modified Risk Tobacco Product Applications A Succinct ENDS Industry Perspective Patricia I. Kovacevic General Counsel, Chief Compliance Officer Presentation to the Food and Drug Law Institute Tobacco Conference,
More informationTRAINING DEVICE OPPORTUNITIES AND SOLUTIONS FOR A CHANGING RESPIRATORY MARKET
TRAINING DEVICE OPPORTUNITIES AND SOLUTIONS FOR A CHANGING RESPIRATORY MARKET Building on his previous articles in ONdrugDelivery on training devices and drug delivery device education, here, Joe Reynolds,
More informationTruScreen Annual Meeting
TruScreen Annual Meeting September 2018 Shareholders Address FY18 ANNUAL MEETING SHAREHOLDERS ADDRESS 27 SEPTEMBER 2018 INTRODUCTION Welcome to the 2018 AGM. FY18 HIGHLIGHTS 2018 was a year of significance
More informationWhy comprehensive TC is essential for successful harm reduction
Why comprehensive TC is essential for successful harm reduction E-cigarette summit London 15 th November 2018 Deborah Arnott Chief Executive ASH (Action on Smoking and Health) Declaration of Interest ASH
More informationThe Role of EPAG in Standards and Regulatory Guidance Development
The Role of EPAG in Standards and Regulatory Guidance Development Jolyon P. Mitchell on behalf of EPAG Session 4: The Remit, Activities and Achievements of The European Pharmaceutical Aerosols Group 1
More informationFLEXIBLE NON-METAL TRAUMA SOLUTIONS.
FLEXIBLE NON-METAL TRAUMA SOLUTIONS. It s time for a solution that fits. Invibio Trauma Device Technology offers a differentiated trauma plate platform made with Ultra-Reinforced polymer Ultra-Reinforced*
More informationKevin Walton, Ph.D. Chief, Clinical Research Grants Branch Division of Therapeutics and Medical Consequences NIDA. No disclosures
Kevin Walton, Ph.D. Chief, Clinical Research Grants Branch Division of Therapeutics and Medical Consequences NIDA No disclosures NIDA Organizational Chart Office of Diversity & Health Disparities Office
More informationThe Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j))
The Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j)) January 12, 2011 Cristi Stark, MS Senior Regulatory Health Project Manager Office
More informationMitch Zeller, Director, Center for Tobacco Products, FDA September 19, 2013 Kansas Public Health Association
Regulatory Public Laws Compliance & Education Policies Science & Enforcement & Communications The FDA Center for Tobacco Products (CTP): Its Role in Reducing Tobacco Use Mitch Zeller, Director, Center
More informationCOMPANY PROFILE. TaiDoc Technology Corporation
TaiDoc Technology Corporation B1-7F., No.127, Wugong 2nd Rd., Wugu Dist., New Taipei City 24888, Taiwan Tel: 886-2-6625-8188 Fax: 886-2-6625-0288 Email: sales@taidoc.com COMPANY PROFILE TD201610A-01 Company
More informationDEVELOPMENT OF PLATFORM INJECTION DEVICES ADDRESSING HUMAN FACTORS AT AN EARLY STAGE FOR DIFFERENT USER GROUPS
DEVELOPMENT OF PLATFORM INJECTION DEVICES ADDRESSING HUMAN FACTORS AT AN EARLY STAGE FOR DIFFERENT USER GROUPS In this article Orfeo Niedermann, Business Development Director, and Jakob Lange, PhD, Account
More informationMARKET OPPORTUNITIES FOR FATTY ESTERS. Prepared by:
MARKET OPPORTUNITIES FOR FATTY ESTERS Prepared by: CPL Business Consultants The Manor House, Howbery Park, Wallingford, Oxfordshire, OX10 8BA Tel: +44 1491 822 844, info@cplconsult.com, www.cplconsult.com
More informationMedical Device VSP Design & Manufacturing. Virtual Surgical Planning
Medical Device VSP Design & Manufacturing Virtual Surgical Planning Overview 3D printing technology is at an inflection point with the medical device industry rapidly adopting 3D printing technology. This
More informationFDA s Action Agenda to Reduce Tobacco Related-Cancer Incidence and Mortality
FDA s Action Agenda to Reduce Tobacco Related-Cancer Incidence and Mortality Lawrence Deyton, M.S.P.H., M.D. Director, FDA Center for Tobacco Products June 11, 2012 FDA s Vision To make tobaccorelated
More informationREQUEST FOR COUNCIL ACTION
REQUEST FOR COUNCIL ACTION Date: 10/14/13 Item No.: 14.c Department Approval City Manager Approval Item Description: Consider an Ordinance Amending City Code Chapter 306: Cigarette and Tobacco Products
More informationPolicy Options for the Regulation of Electronic Cigarettes
Policy Options for the Regulation of Electronic Cigarettes Consultation submission This submission was completed by: (name) Position (if applicable): Evon Currie General Manager, Community and Public Health
More informationUPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP)
UPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP) Mitch Zeller, J.D. Director, FDA May 4, 2017 CENTER FOR TOBACCO PRODUCTS AGENDA Update on Regulations and Guidances: Deeming Update on Science Update
More informationISO Process and Standards Under Development. ISO Principles
Inhalation & Nasal Drugs: The Regulatory Landscape ISO Process and Standards Under Development S.C. Nichols 7 1 ISO Principles ISO standards are developed according to the following principles: Consensus
More informationTowards a Smokefree Generation: A Tobacco Control Plan for England. Tim Baxter, Department of Health, England
Towards a Smokefree Generation: A Tobacco Control Plan for England 1 Tim Baxter, Department of Health, England Smoking rates are falling fast... 25 Adult Smoking prevalence in England (daily and non daily)
More informationPlain Packaging and Intellectual Property Rights. Cheng Tan, Head of Trade Marks
Plain Packaging and Intellectual Property Rights Cheng Tan, Head of Trade Marks chengtan@innovatelegal.co.uk Plain Packaging? Plain Packaging Plain Packaging WHO Framework Convention on Tobacco Control
More informationDeclaration of conformity VEGAPULS 64
Declaration of conformity VEGAPULS 64 Antenna versions PTFE VO (EG) 1935/2004 and VO (EU) 10/2011 as well as acc. to FDA 21 CFR 177.1550 and USP Class VI as well as ADI-free Document ID: 53317 Editing
More informationOraSure Technologies. JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014
OraSure Technologies JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014 Forward-Looking Statements These slides and the associated presentation contain certain forward-looking statements, including
More informationPopulation impacts of snus tobacco initiation and cessation
Population impacts of snus tobacco initiation and cessation Karl Lund, Ph.d Research Director, Tobacco Polarcircle Norway Registered sales of tobacco products in Norway 1909-2014 World war II Cigarettes
More informationGo With the Flow REGULATORY LANDSCAPE. Mark Copley at Copley Scientific
Go With the Flow Image: Guzel Studio shutterstock.com Increasing global requirements for efficacious, inexpensive products to treat respiratory illnesses are driving the development of inhaled generics.
More informationDRAFT FOR COMMENT ( ) All Tobacco Products are Deadly and Addictive: Product Diversity Challenges Regulation and Communication
DRAFT FOR COMMENT (24.01.06) All Tobacco Products are Deadly and Addictive: Product Diversity Challenges Regulation and Communication Jack E. Henningfield, PhD Conference of the Parties Technical Briefing
More informationAradigm Corporation. A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008
Aradigm Corporation A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008 Safe Harbor Statement This presentation contains forward-looking statements
More informationPRODUCT DECLARATION. Purolite C100MRNS. This declaration was prepared by Purolite Corporation in February, 2017.
PRODUCT DECLARATION Purolite C100MRNS This declaration was prepared by Purolite Corporation in February, 2017. Prepared by: Doina Florea Quality & Regulatory Manager Cosmin Catanas Quality Assurance Engineer
More informationEliquid Standardization and Certification Arnaud Dumas De Rauly, President of FIVAPE
Eliquid Standardization and Certification Arnaud Dumas De Rauly, President of FIVAPE 7/10/2014 www.fivape.org 0 Some facts 25,00% 20,00% 15,00% 10,00% 5,00% 0,00% Pricing Sales -5,00% -10,00% -15,00% -20,00%
More informationPlanning For The FDA s 'Deeming Rule' For E- Cigarettes
Law360, New York (September 21, 2015, 3:39 PM ET) -- The 2009 Family Smoking Prevention and Tobacco Control Act (TCA)[1] gave the U.S. Food and Drug Administration the authority to oversee the manufacture,
More informationWelcome to Galenicum! APRIL, 2013
Welcome to Galenicum! APRIL, 2013 Our corporate image comes from the sunrise. Night represents disease, daylight means health and the sunrise stands for overcoming GALENICUM CORPORATE PRESENTATION 3 Who
More informationPRODUCT DECLARATION. Purolite A430MR. This declaration was prepared by Purolite Corporation in February, 2017.
PRODUCT DECLARATION Purolite A430MR This declaration was prepared by Purolite Corporation in February, 2017. Prepared by: Doina Florea Quality & Regulatory Manager Cosmin Catanas Quality Assurance Engineer
More informationIndustry Post-Regulation. E-Cigarette Summit Tim Phillips, ECigIntelligence. 17 th November
Industry Post-Regulation E-Cigarette Summit 217 Tim Phillips, ECigIntelligence 17 th November 217 www.ecigintelligence.com Agenda 1 2 3 Post-TPD: Has regulation been a success? Heated Tobacco: a success?
More informationLet s share our talents
Let s share our talents 2 The global solution in dental implantology As the first dental implant provider to develop a comprehensive offer, Anthogyr designs, manufactures and distributes a complete range
More informationMARKETING STANDARDS FOR MEMBERSHIP
MARKETING STANDARDS FOR MEMBERSHIP The Vapor Technology Association (VTA) is a leading national trade association in the electronic cigarette and vapor product industry. VTA represents the manufacturers,
More informationEU5 Bariatric Surgery Procedures Outlook to 2020
EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationBrain research supported by the European Union
Brain research supported by the European Union Lara Passante, PhD Health Directorate Directorate-General for Research & European Commission FENS Featured Regional Meeting 11-14 Septembre 2013 Prague Neuroscience:
More informationDrug/Device Combination Products: Bioequivalence
Drug/Device Combination Products: Bioequivalence Three stories:. The story of Nasal and Inhalation Product BE 2. The story of the Generic Auto-Injector 3. The story of User Interface Considerations Bioequivalence
More informationCan you please describe your role within the company? How did you get to be in this position, and what are your responsibilities?
Immunservice questionnaire: 1. Please can you give us a short description of what your firm does? What healthcare areas does your firm specialise in? Immunservice is the expert for innovative well-tolerated
More informationPOSSIBLE REVISION OF THE TOBACCO PRODUCTS DIRECTIVE 2001/37/EC PUBLIC CONSULTATION DOCUMENT
POSSIBLE REVISION OF THE TOBACCO PRODUCTS DIRECTIVE 2001/37/EC DG SANCO 2010 PUBLIC CONSULTATION DOCUMENT Answer given by the General Direction of Public Health of the Spanish Ministry of Health and Social
More informationPUBLIC CONSULTATION DOCUMENT
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Directorate C Public Health and Risk Assessment POSSIBLE REVISION OF THE TOBACCO PRODUCTS DIRECTIVE 2001/37/EC PUBLIC CONSULTATION DOCUMENT
More informationPHARMACEUTICAL PACKAGING
vr100 PHARMACEUTICAL PACKAGING Bottles - Nasal Pumps - Oral Spray Pumps 2 3 Welcome to Raepak, a company devoted to innovation and the supply of liquid packaging for clients around the world. We aim to
More informationFor personal use only. Investor Briefing. Bayswater, 1 st December 2016
Investor Briefing Bayswater, 1 st December 2016 Introduction Samantha Cheetham Chief Executive Officer To be an innovative leader in the dental industry, developing our people and partnering with dentists
More informationThe Voice of Local Public Health in New York State. May 12, 2014
The Voice of Local Public Health in New York State May 12, 2014 Testimony before the Senate Standing Committee on Health To consider including electronic cigarettes in the existing Clean Indoor Air Act
More informationClaims about health in ads for e-cigarettes. CAP and BCAP s regulatory statement
Claims about health in ads for e-cigarettes CAP and BCAP s regulatory statement Contents 1. Executive Summary... 2 2. Policy background and the decision to consult... 4 3. Decisions... 6 4. Consequence
More informationThe Changing Landscape of Tobacco: E-Cigarettes, E-Hookahs and More
38th Annual Family Medicine Intensive Review Course The Changing Landscape of Tobacco: E-Cigarettes, E-Hookahs and More Debbie Rushing, LADAC, CTTS-M Associate Branch Chief Tobacco Prevention and Cessation
More informationAsia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020
Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3
More informationChina Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020
China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 Reference Code: GDMECC0079DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
More informationFDLI Annual Conference
FDLI Annual Conference Panel Tobacco Harm Reduction: Opportunities & Regulatory Pathways to Achieve May 5, 2017 Joe Murillo Vice President, Regulatory Affairs Altria Client Services Panel Discussion at
More informationPrident SmartSourcing Services: Outsourcing for Today s Cost-Effective Dental Lab
Prident SmartSourcing Services: Outsourcing for Today s Cost-Effective Dental Lab Prident prosthetics.dentsply.com 1-800-618-2431 Prident SmartSourcing Services A Progressive Business Model. What challenges
More informationTobacco-related risk perceptions in the regulation of tobacco products at the FDA Center for Tobacco Products
Tobacco-related risk perceptions in the regulation of tobacco products at the FDA Center for Tobacco Products David B. Portnoy, PhD, MPH Conrad J. Choiniere, PhD Office of Science FDA, Center for Tobacco
More informationRESULTS AT A GLANCE. FDA Oversight of Tobacco Manufacturing Establishments. HHS OIG Data Brief August 2017 OEI
HHS OIG Data Brief August 2017 OEI-01-15-00300 FDA Oversight of Tobacco Manufacturing Establishments RESULTS AT A GLANCE The Tobacco Control Act authorized FDA to regulate domestic tobacco manufacturers
More information